Although the antagonism of LPAR1/3 protects against podocyte loss in endothelial nitric oxide synthase (eNOS)−/− db/db mice, a type 2 diabetes model [15], the role of LPA/LPAR1 signaling in podocyte damage during DN remains unexplored. This evidence concerns the gene LPAR1 and liver dysplastic nodule.